Comparing the current results to its competitors, Oramed Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 12.06 %, recorded in the same quarter.
Oramed Pharmaceuticals Inc Net Income in the 2 quarter 2026 grew year on year by 489.41%, faster than the Oramed Pharmaceuticals Inc's competitors average income growth of 204.69 %
Oramed Pharmaceuticals Inc's Comment on Competition and Industry Peers
The company operates in a highly competitive pharmaceutical research and development environment, facing competition from major pharmaceutical companies, specialized biotechnology firms, academic institutions, and governmental agencies with greater financial, technical, and marketing resources. Key competitive factors include scientific and technological capabilities, patent protection, speed to market, regulatory approval, and commercialization capacity. In the diabetes treatment sector, competitors offer established and emerging therapies such as insulin injections, insulin pumps, oral medications that enhance insulin response or production, GLP-1 receptor agonists (both injectable and oral), and lifestyle interventions. The widespread use of GLP-1 receptor agonists for diabetes and weight management presents significant competitive pressure. The company's competitive position relies on attracting skilled personnel, developing proprietary products, securing patent protection, and obtaining capital. If approved, the company’s oral insulin capsule will compete based on efficacy, safety, patient convenience, and patent position; however, competitors may develop superior products or achieve greater market acceptance.
Publicly Traded Peers of Oramed Pharmaceuticals Inc
Adagene Inc Share Performance
+3.47%
This Quarter
Adagene Inc
Profile
Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.
ImmIx Biopharma Inc is a biotechnology company that focuses on developing novel therapeutics for the treatment of cancer. Their business model involves conducting extensive research and development to discover and optimize drug candidates, followed by preclinical and clinical testing to assess their safety and effectiveness. They aim to collaborate with pharmaceutical companies or seek licensing agreements to further develop and commercialize their biopharmaceutical products.
Aprea Therapeutics Inc is a biopharmaceutical company with a business model focused on developing and commercializing innovative cancer therapies. They aim to leverage their proprietary discovery platform to identify and develop small molecules that selectively target and restore the tumor suppressor protein p53. Their business strategy includes conducting clinical trials, seeking regulatory approvals, and partnering with other organizations for commercialization and distribution.
Sources:
Oramed Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Oramed Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
